The firm now has a "hold" rating on the stock. The highest and lowest price target given by the brokerage firms to the equity are $40 and $28, respectively.
Other research analysts have also issued research reports about the stock. RBC Capital Markets reaffirmed an "outperform" rating and set a $58.00 price target (down previously from $71.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, November 30th. Finally, Nordea Investment Management AB raised its stake in shares of Teva Pharmaceutical Industries Limited by 2.4% in the third quarter. The firm has a market capitalization of $32.82 billion, a price-to-earnings ratio of 18.810 and a beta of 0.58. BTIG Research lowered shares of Teva Pharmaceutical Industries Limited from a buy rating to a neutral rating in a research report on Sunday, December 4th. The company's quarterly performance represents an optimistic momentum of 17.42 percent, with a surge of 11.03 percent in the stock price over the last one month. The stock has an average rating of "Buy" and an average price target of $53.88.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 5.638% during mid-day trading on Monday, reaching $34.005. 17,644,502 shares of the company's stock traded hands. The company's 50 day moving average is $34.51 and its 200-day moving average is $42.93. Teva Pharmaceutical Industries Limited has a 52 week low of $31.90 and a 52 week high of $59.35. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has underperformed the index by 6.94% in the last 4 weeks. On average, 24 analysts polled by Thomson Reuters expected the company to report profit per share of $1.35 for the quarter. The business earned $6.25 billion during the quarter, compared to analysts' expectations of $6.26 billion. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has tumbled 6.53% during the past week and has dropped 5.24% in the last 4 week period. The company's revenue was up 33.0% compared to the same quarter previous year. Excluding certain items, per-share earnings were $1.38, up from $1.28 a share in the prior-year quarter. Equities analysts expect that Teva Pharmaceutical Industries Limited will post $5.11 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, March 20th. Teva Pharmaceutical Industries Limited's dividend payout ratio is 67.44%. If you are reading this news story on another site, it was illegally copied and reposted in violation of worldwide copyright laws.
"Teva Pharmaceutical Industries Limited (TEVA) PT Lowered to $40.00 at Maxim Group" was published by BBNS and is the sole property of of BBNS.
Investors say Teva, which faces pricing pressure in its core generics business and recently lost patent protection on its key branded drug Copaxone for multiple sclerosis, must choose a new CEO with extensive pharmaceutical experience. The Predicted Move on the 7th day after Teva Pharmaceutical Industries Limited (NYSE:TEVA) will release its earnings at about 2%. EPS or Earning per Share stands at $1.73. Cardinal Capital Management raised its stake in Teva Pharmaceutical Industries Limited by 4.4% in the third quarter. CQS Cayman LP's holdings in Teva Pharmaceutical Industries Limited were worth $497,000 at the end of the most recent quarter. State Street Corp boosted its stake in Teva Pharmaceutical Industries Limited by 477.2% in the fourth quarter.
The company is now in the middle of appealing that decision, but if the FDA approves competitors that then stage at-risk launches, Teva could see $1 billion to $1.3 billion wiped off its top line and 75 cents to 95 cents in lost EPS, Peterburg said.
Among analysts and investors, a widespread belief is that Teva could split in two-one side, the company's generics business, the other, its branded drug company.